We hereby submit announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on your records.
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ambalal Sarabhai Enterprises has disclosed that Co-Diagnostics Inc. (NASDAQ: CODX), its joint venture partner in CoSara Diagnostics Pvt. Ltd., has engaged Maxim Group LLC as exclusive financial advisor. The advisor will help explore strategic alternatives for CoSara, including a potential merger with a Special Purpose Acquisition Company (SPAC) listed on a U.S. exchange. CoSara, established in 2017, is an India-focused molecular diagnostics JV between Co-Diagnostics and Ambalal Sarabhai's subsidiaries (Synbiotics and Asence Inc.). No binding agreement, valuation, or timeline has been announced yet — this is an early-stage exploration of options.
Positive sentiment signal for Ambalal Sarabhai shareholders, as a successful SPAC transaction could unlock value in its CoSara Diagnostics stake by giving it a U.S. listing. However, there is no concrete deal or offer yet, so the stock reaction may be limited until further clarity emerges.